: China recently approved Exdensur (severe asthma) and Blenrep (multiple myeloma).
: The current forward dividend yield is approximately 3.2% to 3.6% . buy gsk shares
: The payout ratio sits at a healthy 38%–51% of earnings, suggesting the dividend is well-covered by cash flow. ⚠️ The Bear Case: Risks to Watch : China recently approved Exdensur (severe asthma) and
🎯 : GSK is scheduled to report its Q1 2026 earnings on April 29, 2026 , with analysts expecting revenue of roughly $10.24 billion . buy gsk shares